A growing Bethesda IV thyroid nodule: how far should the first operation go?
A 58-year-old woman is referred with a 4.2 cm left thyroid nodule found incidentally. She reports mild dysphagia to solids and a pressure sensation, but no hoarseness. The nodule has grown from 3.0 cm to 4.2 cm over 18 months. Ultrasound shows a solid, hypoechoic nodule with smooth margins and no microcalcifications; there is no cervical lymphadenopathy. TSH is 1.8 mIU/L; anti-TPO antibodies are negative. Fine-needle aspiration is reported as Bethesda IV, follicular neoplasm. Vocal fold mobility is normal bilaterally. The trachea is midline, and she has no history of neck irradiation or thyroid cancer. She is euthyroid and otherwise healthy. She is a schoolteacher and is worried about voice change. She asks whether she needs a total thyroidectomy or if a lobectomy is enough, and whether molecular testing is worthwhile.
1. What is your diagnostic and surgical plan, and how does molecular testing alter it?
Read the worked answer
Bethesda IV carries a 25-40% risk of malignancy, usually follicular carcinoma, and cannot be resolved by cytology alone. Because the nodule is 4.2 cm, growing, and causing dysphagia, surgery is indicated regardless. Molecular testing is worthwhile if it will change the extent of the first operation: a benign classifier such as Afirma GSC supports lobectomy, while a suspicious ThyroSeq or Afirma result supports total thyroidectomy. If testing is unavailable or delayed, diagnostic lobectomy with intraoperative frozen section is acceptable, but frozen section cannot reliably distinguish follicular adenoma from carcinoma. I would discuss both paths. If she chooses lobectomy and final pathology is benign, no further surgery is needed; if carcinoma is found, completion thyroidectomy may be required based on risk features.
2. If final pathology shows follicular thyroid carcinoma, what determines completion thyroidectomy and radioiodine?
Read the worked answer
Completion thyroidectomy is generally recommended when the initial lobectomy reveals follicular carcinoma larger than 4 cm, angioinvasion, extrathyroidal extension, or positive margins, because these features increase recurrence risk and make radioiodine more likely. For a 4.2 cm minimally invasive follicular carcinoma confined to the thyroid, total thyroidectomy is often favored upfront; if lobectomy was done, completion is reasonable. Radioiodine is considered for high-risk features, not for low-risk intrathyroidal disease. Risk stratification should follow American Thyroid Association criteria, and the decision should be made in a multidisciplinary tumor board.
3. How do you counsel her about voice and parathyroid risk, and what intraoperative adjuncts do you use?
Read the worked answer
Counsel that total thyroidectomy carries a small but real risk of permanent recurrent laryngeal nerve injury, about 1-2% in experienced hands, and permanent hypoparathyroidism, about 1-3%, higher with central neck dissection or reoperation. Use intraoperative nerve monitoring as an adjunct, not a substitute for identifying the nerve. Identify all parathyroid glands, preserve their blood supply, and autotransplant any devascularized gland into the sternocleidomastoid. For a schoolteacher, voice is critical; document baseline voice, use a nerve monitor, and refer early for voice therapy if there is postoperative weakness. Calcium and parathyroid hormone should be checked after total thyroidectomy.